Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 2 1

Status

Recruiting 26Active not recruiting 18Completed 12Unknown 6Withdrawn 4Terminated 3Not yet recruiting 2Suspended 1Approved for marketing 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Endocrine 4NET 3CNS 2Head & Neck 1Gastrointestinal 1

Conditions

Neuroendocrine Tumors 3Pheochromocytoma 2Paraganglioma 2Pituitary Neoplasms 1Parathyroid Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1Carcinoma, Medullary 1

Interventions

Cyclophosphamide 129Cisplatin 119Radiotherapy 115pembrolizumab 111Carboplatin 97Paclitaxel 96Gemcitabine 96Magnetic Resonance Spectroscopy 80Nivolumab 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Biopsy 53Doxorubicin 52fludarabine 51Drug Therapy 45durvalumab 44Cytarabine 44Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Surveys and Questionnaires 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Withdrawn × lutetium Lu 177 dotatate × Clear all
NCT04614766 2024-04-29

SPORE-3

University of Iowa

Phase 1/2 Withdrawn
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT03923257 2021-06-08

Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents

University of Iowa

Phase 1/2 Withdrawn
CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT04106843 2020-09-07

Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

M.D. Anderson Cancer Center

Phase 2 Withdrawn
CNSEndocrineHead & Neck

Paraganglioma, Parathyroid Neoplasms, Pheochromocytoma, Pituitary Neoplasms, Carcinoma, Medullary

NCT01860742 2016-04-05

CASTOR

Jules Bordet Institute

Phase 3 Withdrawn
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡